Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Durvalumab And Tremelimumab

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT03430895Phase 2CompletedPrimary

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Showing all 1 trials

Research Network

Common Treatments

  • Durvalumab And Tremelimumab1
  • Durvalumab1
  • Tremelimumab1

Active Sponsors

  • Memorial Sloan Kettering Cancer Center1
  • AstraZeneca1

Top Investigators

Related Conditions

  • Adenocarcinoma Of The Bladder1
  • Metastatic Bladder Cancer1
  • Small Cell Of The Bladder1
  • Squamous Cell Carcinoma Of The Bladder1

Activity Timeline